Shares of Evoke Pharma Inc. (NASDAQ:EVOK) traded up 10.4% on Wednesday . The company traded as high as $2.78 and last traded at $2.77, with a volume of 1,345,277 shares. The stock had previously closed at $2.51.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a research report on Tuesday, May 3rd. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a research report on Saturday, May 14th. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a research report on Thursday, May 12th. Rodman & Renshaw cut shares of Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research report on Monday, July 18th. Finally, Feltl & Co. cut shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. Evoke Pharma presently has a consensus rating of “Hold” and a consensus target price of $13.34.

The company has a 50-day moving average of $5.67 and a 200 day moving average of $4.76. The company’s market cap is $19.04 million.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. Equities analysts forecast that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.